The UK medicines regulator (MHRA) gave the so-called bivalent vaccine made by U.S. drug company Moderna MRNA.O conditional approval as a booster for adults on Monday.

Britain’s Joint Committee on Vaccination and Immunisation (JCVI) is now expected to soon issue a recommendation on how the vaccine should be deployed in the country.

The MHRA’s decision was based on clinical trial data that showed the booster triggered “a strong immune response” against both Omicron (BA.1) and the original 2020 virus, it said.

Moderna said in June trial data showed that when given as a fourth dose, the variant-adapted shot raised virus-neutralizing antibodies by eight-fold against Omicron.

The MHRA also cited an exploratory analysis in which the shot was found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5.

No serious safety concerns were identified with this new formulation, the agency added.

The UK government said last month a vaccine booster programme would begin in “early autumn” and that shots would offered to over 50s, individuals in clinical risk groups, frontline workers and care homes staff.

While existing Covid-19 vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the virus has evolved.

“The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives,” MHRA Chief Executive June Raine said in a statement.

“What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”

The UK Health and Security Agency (UKHSA), which oversees vaccine procurement among other responsibilities, did not immediately respond to a request for comment.

European Medicines Agency (EMA) officials expect Covid-19 variant-adapted vaccines to be approved in the European Union by September, and have signalled the regulator is open to using shots targeting the older BA.1 variant this autumn, given those specifically targeting newer subvariants are further behind in clinical development.

In contrast, the U.S. Food and Drug Administration (FDA) has said it will seek the specific inclusion of the newer BA.4 and BA.5 offshoots of Omicron in any new shots used domestically.

Apart from Moderna, partners Pfizer Inc PFE.N and BioNTech 22UAy.DE have also been testing versions of their mRNA vaccine modified to combat Omicron variants.

Meanwhile, Sanofi SASY.PA and partner GSK GSK.L are working on a protein-based vaccine that targets the Beta subvariant, which dominated for some time last year.

By Natalie Grover

(Reporting by Natalie Grover in LondonEditing by David Goodman and Mark Potter)